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A B S T R A C T
Purpose: In epilepsy with continuous spikes and waves during slow sleep (CSWS), which is a
representative epileptic syndrome of secondary bilateral synchrony (SBS), the urgent suppression of this
electroencephalographic (EEG) abnormality may be necessary to prevent the progression of
neuropsychological impairments. The purpose of this study was to determine the efﬁcacy of
levetiracetam (LEV) on SBS, seizure frequency, and neuropsychological impairments in children with
refractory epilepsy.
Methods: Eleven (seven male and four female) patients with refractory epilepsy with SBS on EEG, aged
between 4.7 years and 11.3 years, were included in this study. After a 3-month baseline period, the
patients were given LEV at an initial dose of 10 mg/kg/day for the ﬁrst week, followed at increments of
5 mg/kg/day every week, up to 20 mg/kg/day. The LEV dose was then adjusted up to a maximum of
60 mg/kg/day, according to the clinician’s judgment. EEG recordings and clinical evaluations were
performed every 3 months, focusing on SBS. The occurrence of SBS was then scored, and the
relationship between the score and the response to LEV treatment was evaluated. In comparison with
the baseline SBS frequency, the EEG response to LEV treatment was classiﬁed, and responders were
identiﬁed as having a 50% reduction in SBS frequency. In addition, in comparison with the baseline
seizure frequency, response to LEV treatment was classiﬁed. Responders were identiﬁed as patients
with complete cessation (100% seizure control) and a response of 50% reduction in seizures.
Furthermore, neuropsychological impairments such as hyperactivity, impulsiveness, and inattention
were evaluated before and after LEV treatment.
Results: Eight patients (72.7%) were considered responders. In addition, all eight patients were also
considered responders for clinical seizures. Furthermore, 7 of 8 (87.5%) patients with response showed
decreased hyperactivity and impulsivity after LEV administration.
Conclusions: The present data clearly indicate the usefulness of LEV in reducing both SBS on EEG and
seizure frequency. LEV represents an important addition to the treatments available for refractory
childhood epilepsies with SBS on EEG.
 2012 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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Of the new antiepileptic drugs (AEDs), levetiracetam (LEV) has
been approved as adjunctive treatment for new partial epilepsy in
adults and children.1–3 Studies published on the use of LEV in
children with epilepsy have shown excellent pharmacokinetic and
tolerability proﬁles, with few deleterious effects on cognitive* Corresponding author at: Department of Pediatrics, Faculty of Medicine,
University of Yamanashi, 1110 Chuo, Yamanashi 409-3898, Japan.
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1059-1311/$ – see front matter  2012 British Epilepsy Association. Published by Else
http://dx.doi.org/10.1016/j.seizure.2012.10.003function and no known pharmacokinetic interactions.4 Further-
more, no teratogenic, mutagenic, or immunotoxic effects have
been associated with administration of LEV in several animal
species.2
For partial epilepsies, the relationships between seizures and
interictal epileptiform discharges are controversial, but some
interictal epileptiform activities have subtle clinical manifesta-
tions. LEV reduces the incidence of seizures1 and interictal
epileptiform discharges5 in adult patients with localization-related
epilepsy. However, little is known about these LEV efﬁcacies for
children with epilepsy.
Secondary bilateral synchrony (SBS) is the term given by Tukel
and Jasper6 to ‘‘bilaterally synchronous discharges which can bevier Ltd. All rights reserved.
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been determined whether epilepsy with continuous spikes and
waves during slow sleep (CSWS), which is a representative
epileptic syndrome of SBS, is primary bilateral synchrony or
SBS. Many of these children develop severe cognitive and
behavioral deterioration that is unresponsive to medical treatment
as the disease progresses.7 In previous studies, seizures and the
duration of paroxysmal anomalies appear to have been associated
with prefrontal lobe growth abnormalities, which are associated
with neuropsychological problems in CSWS.8,9 These studies
suggest that the urgent suppression of this electroencephalograph-
ic (EEG) abnormality may be necessary to prevent the progression
of neuropsychological impairments. Accordingly, it is important to
identify and use the best treatment options to remit seizures and
EEG abnormalities as soon as possible to achieve the optimal
prognosis in CSWS.10
The purpose of this study was to determine the efﬁcacy of LEV
on SBS, seizure frequency, and neuropsychological impairments in
children with refractory epilepsy.
2. Methods
Eleven (seven male and four female) patients with refractory
epilepsy with SBS on EEG, aged between 4.7 years and 11.3 years
(mean, 7.5 years) at enrolment, were included in this study. The
primary criterion for patient selection was the presence of frequent
SBS on EEG recordings. In addition, the following criteria also had
to be fulﬁlled: (1) between 1 and 18 years old; (2) seizures
refractory to at least two ﬁrst-line AEDs (appropriate AED for each
seizure type or epileptic syndrome, with therapeutic concentra-
tions of AEDs); (3) at least four seizures a month during the 3
months before LEV administration; (4) neuropsychological impair-
ments such as hyperactivity, impulsivity, and inattention, as
referred to in the Diagnostic and Statistical Manual of Mental
Disorders, fourth edition (DSM-IV)11; and (5) at least 6 months of
follow-up. Age at onset of epilepsy ranged from 3.1 years to 6.5
years (mean, 4.4 years). The mean duration of epilepsy history was
3.3 years (range, 1.6–4.8 years). All patients were affected by
localization-related epilepsy or CSWS. In 10 patients, partial
seizures evolved to secondary generalization. Participants in this
study were taking a stable regimen of at most two or three
concomitant AEDs, such as valproate sodium (VPA), zonisamide
(ZNS), ethosuximide (ESM), and clobazam (CLB). However,
children who were receiving carbamazepine (CBZ) at the time of
ﬁrst evaluation were excluded. The mean number of AEDs tried
before introducing LEV treatment was 4.1 (range, 2–6).
After a 3-month baseline period, patients with epilepsy were
given LEV at an initial dose of 10 mg/kg/day twice daily, which was
increased to 15 mg/kg/day after 1 week, and then increased to
20 mg/kg/day after 1 week. During this period, LEV doses could be
increased up to 60 mg/kg/day (or 3000 mg/day), according to the
clinician’s judgment. The goal of treatment in this protocol was to
obtain seizure response (50% seizure reduction) without adverse
effects. The LEV dose was not increased in cases of complete
seizure control and could be decreased in cases of adverse effects.
The ﬁnal dose regimen that was reached was maintained
unchanged during the ﬁrst 3 months of the evaluation period
and could be adjusted for the following 3 months in cases of
inadequate seizure control or adverse effects. The co-medication
remained unchanged from baseline to the end of the 6-month
evaluation period.
EEGs were performed on a 12- or 16-channel machine every 3
months. The duration of tracings was at least 20 min. For inclusion,
it was necessary that at least one EEG be obtained without drug
induction, showing a clear sequence of awake–drowsy–sleep–
arousal–awake states. For this reason, parents were instructed tokeep their children awake the night before the visit. Intermittent
photic activation was done routinely, and hyperventilation was
used when age permitted.
EEG studies were coded by number and read independently by
two pediatric epileptologists or neurologists blinded to the identity
of the patients. Agreement about the presence of SBS was required
for inclusion of the patient in the study. According to a previous
paper by Blume and Pillay12 apparent SBS occurring exclusively
during photic stimulation was not included. Recordings included
sleep in the majority of patients.
EEG recordings and clinical evaluations were performed every 3
months, focusing on SBS. The occurrence of SBS during slow wave
sleep on EEG with bipolar montage was scored, and the
relationship between the score and the response to LEV treatment
was evaluated. The spikes localized in only one hemisphere were
not counted, since on EEGs with frequent SBS, such as CSWS, they
were difﬁcult to identify. The 3-month period before starting
treatment was used as the baseline period for SBS frequency. SBS
frequency on EEG was deﬁned as the mean SBS frequency per
minute. SBS frequency was compared in the same sleep stage in
each patient. Six months later, the response to the dose increment
for maintenance was assessed. In comparison with the baseline
SBS frequency, the EEG response to LEV treatment was classiﬁed as
follows:complete disappearance; response (50% reduction in SBS
frequency); no response (<50% reduction to <50% increase in SBS
frequency); and exacerbation (50% increase in SBS frequency).
Responders were identiﬁed as patients with complete disappear-
ance and response.
In addition, baseline seizure frequency, type, and duration were
recorded by parents and caregivers over a period of 3 months
before starting treatment with LEV. The numbers of seizures were
recorded by parents and caregivers both at home and at day
nursery/kindergarten/school. Seizure frequency, type, and dura-
tion, as well as adverse effects, were recorded in an epilepsy diary
completed by parents and/or caregivers. Seizure frequency was
deﬁned as the mean seizure frequency per month. Six months after
the dose increment for maintenance therapy, the response was
assessed. In comparison with the baseline seizure frequency,
response to LEV treatment was classiﬁed as follows: complete
cessation (100% seizure control); response (50% reduction in
seizures); minimal response (<50% reduction in seizures); no
response (no change in frequency); and exacerbation (50%
increase in seizure frequency). Seizure-free was deﬁned as
complete cessation for more than 3 months. Responders were
identiﬁed as patients with complete cessation and response; they
were followed-up for more than 6 months. Furthermore,
neuropsychological impairments were evaluated before and after
LEV treatment.
The signiﬁcance of differences was evaluated by the t-test and
the Bonferroni test; P < 0.05 was accepted as a signiﬁcant result.
The study was carried out in accordance with the Declaration of
Helsinki. Since LEV is not approved for children in Japan, informed
consent was obtained from the parents of each patient following a
full explanation of the procedures to be undertaken.
3. Results
The mean dose of LEV was 44.8 mg/kg/day (range, 19.4–
57.7 mg/kg/day). The ﬁnal mean dose was 1644 mg/day (450–
2250 mg/day), using a b.i.d. dose schedule. Demographic data and
baseline characteristics are summarized in Table 1.
Nine of eleven (81.8%) patients were considered responders for
clinical seizures. In addition, 5 of 11 (46.4%) patients showed
complete seizure cessation. Furthermore, all 5 frontal lobe epilepsy
(FLE) patients showed seizure response.
Table 1
Demographic data and baseline characteristics. M, male; F, female; CSWS, epilepsy
with continuous spike and wave during slow sleep; FLE, frontal lobe epilepsy; ABPE,
atypical benign partial epilepsy of childhood; TLE, temporal lobe epilepsy.
Case Age
(years)
Sex Age of
epilepsy
onset (years)
Prior
AED (n)
Epileptic
syndrome
1 6.7 M 3.9 4 CSWS
2 7.1 M 4.1 5 FLE
3 4.7 F 3.1 3 FLE
4 5.6 F 3.4 4 FLE
5 9.2 M 6.5 4 ABPE
6 8.4 F 4.3 6 CSWS
7 6.2 M 4.1 3 FLE
8 7.6 M 4.2 4 ABPE
9 11.3 M 5.8 6 CSWS
10 4.9 F 3.2 2 FLE
11 10.3 M 6.1 4 TLE
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patients (72.7%) were considered responders because they
showed a reduction of 50% in SBS frequency on EEG. In addition,
all 8 patients were considered responders for clinical seizures.
Furthermore, 7 of 8 (87.5%) responder patients showed decreases
in hyperactivity and impulsivity after LEV administration. Two of
seven (28.6%) patients fulﬁlled the criteria for attention deﬁcit/
hyperactivity disorder of DSM-IV.11 The efﬁcacy for SBS on EEG
was not apparent in one patient, but efﬁcacy for clinical seizures
was seen. In this patient (Case 3), efﬁcacy for clinical seizures was
achieved 2 months after LEV administration, but efﬁcacy for SBS
was not seen 9 months after LEV administration. Therefore,
continuation of treatment for so long was justiﬁed in a child who
responded clinically but did not respond on EEG. In the remaining
two patients, there were no exacerbations. No efﬁcacy for SBS or
seizures was seen in two patients, but efﬁcacy for emotional state
was evident. Therefore, continuation of treatment for so long was
justiﬁed in these children who did not respond. The efﬁcacy of LEV
for SBS on EEG and clinical seizures is summarized in Table 2. In 3
children (27.3%), there was a disappearance of SBS and paroxys-
mal abnormalities (Fig. 1). In 5 children (45.5%), there was a major
decrease in SBS and paroxysmal abnormalities. In contrast, 6
children (54.5%) became seizure-free for the entire study 6
months after LEV administration, 3 (27.3%) showed a >50%
reduction in seizure frequency for the entire 6 months, and 1
(9.1%) showed minimal response. In a further 1 patient (9.1%),
seizure frequency remained unchanged, but no patients experi-
enced an increase in seizure frequency. Serial data showed no
change in patients showing responder status. Thus, tolerance to
the anticonvulsant did not appear. Seizure reduction wasTable 2
The clinical efﬁcacy of LEV for SBS on EEG and clinical seizures. SBS, secondary bilater
impulsivity; IA, inattention; VPA, valproate sodium; CLB, clobazam; ZNS, zonisamide; 
Case Frequency of SBS
(times/min)
Seizure frequency
(times/week)
Neuropsych
impairment
Pre Post Pre Post Pre 
1 54 0 6 0 HA/IP (+) 
2 31 12 9 0 HA/IP (+) 
3 28 25 6 1 HA (+) 
4 37 0 10 0 HA/IP (+) 
5 39 8 7 0 HA/IA (+) 
6 58 52 4 3 HA/IP (+) 
7 21 5 8 2 HA (+) 
8 33 9 4 0 HA (+) 
9 61 0 7 0 HA/IP (+) 
10 27 7 6 1 HA (+) 
11 18 15 1 1 HA (+) demonstrated in the patients with atypical benign partial epilepsy
of childhood (ABPE) and CSWS patients (Table 3). Both patients
with ABPE showed complete disappearance of SBS and clinical
seizures. Furthermore, 2 of 3 patients with CSWS showed
complete disappearance of SBS and clinical seizures. On the other
hand, 4 of 5 patients with frontal lobe epilepsy showed a major
reduction of SBS. In contrast, no patients with temporal lobe
epilepsy showed any reduction of SBS or clinical seizures (Table
3). Concomitant treatment was not modiﬁed during LEV
administration.
Adverse events occurred in only 1 patient (9.1% of the total
initial treatment group). The treatment-related adverse effect was
drowsiness. This symptom was mild in this patient, and LEV
discontinuation was not necessary. Hematological and biochemi-
cal tests were normal in all patients. None of the events causing
hospitalization was considered by the investigators to be related to
the study medication.
No clinically relevant, drug-related changes in clinical labora-
tory values, vital signs, physical examinations, neurological
assessments, or electrocardiography were identiﬁed during the
study.
4. Discussion
The results of this study indicate that LEV treatment may be
effective in reducing EEG interictal abnormalities such as SBS in
patients with refractory epilepsy. In addition, LEV treatment may
be effective in reducing seizure frequency in localization-related
epilepsies. Furthermore, the present data also suggest the
usefulness of LEV in decreasing hyperactivity and impulsivity.
Freedom from SBS for 6 months was taken as the primary
indicator of efﬁcacy; disappearance of SBS was found in 50% of
seizure-free patients. More than one-third of the present patients
achieved freedom from SBS and epileptiform discharges over the
entire study period for a mean of 9.4 months. The reduction in SBS
was signiﬁcantly related to the reduction in seizure frequency. All
patients who achieved complete remission in SBS also showed an
improvement in seizures. In a previous report, the reduction in
epileptiform EEG abnormalities in juvenile myoclonic epilepsy was
signiﬁcantly related to the reduction in days with myoclonia.13 In
other reports, there were complete recoveries in 66.7% (2 of 3),14
50.0% (3 of 6),15 and 55.0% (11 of 20)16 of patients with drug-
resistant CSWS after LEV treatment. Moreover, a reduction in EEG
abnormalities and improvement in cognitive and behavioral
functions were described with LEV in 9 cryptogenic and 3
symptomatic cases with CSWS.4 The present results are consistent
with these ﬁndings.al synchrony; LEV, levetiracetam; AED, anti-epileptic drug; HA, hyperactivity; IP,
CBZ, carbamazepine; LTG, lamotrigine; ESM, ethosuximide; SLT, sulthiame.
ological
s
LEV dosage (mg/kg/day) Present AED
Post
HA/IP () 30.2 VPA + CLB + LEV
HA/IP () 19.4 VPA + ZNS + LEV
HA (+) 35.5 CBZ + LTG + LEV
HA/IP () 20.6 VPA + LEV
HA/IA () 30.6 VPA + ESM + LEV
HA/IP (+) 40.8 VPA + CLB + LEV
HA () 31.3 ZNS + LEV
HA () 40.1 VPA + SLT + LEV
HA/IP () 57.7 VPA + CLB + LEV
HA (+) 24.2 ZNS + LEV
HA (+) 45.1 ZNS + LEV
Fig. 1. EEG of patient 1 before (A) and after (B) introduction of LEV, recorded during sleep. EEG shows bilateral synchronous spike and slow-wave discharges (A). Six months
after adding LEV, the EEG shows a great deal of improvement (B). The EEG shown is in bipolar montage, and the actual analysis was performed on bipolar montages for all
EEGs.
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effective in both partial and generalized seizures.17 LEV, an add-on
AED for partial-onset seizures in adults, shows good pharmacoki-
netics and tolerability in children, and it also demonstrates good
efﬁcacy in partial seizures and some generalized seizures.18,19
Moreover, LEV is effective in treating children with speciﬁc
epilepsy syndromes, such as CSWS, resulting in seizure reduction,
improvement of alertness, and cessation of electrical status
epilepticus during the sleep pattern on EEG.20 In CSWS, the
seizures demonstrate several types. In addition, the EEG pattern of
CSWS consists of bilateral synchronous discharges. Focal spikes
tend to be frontal. In our previous study, LEV appeared to
demonstrate efﬁcacy especially for frontal lobe epilepsy.21 Thus,
LEV may have a positive effect on SBS. The present results are in
agreement with these ﬁndings.
In the present study, frontal lobe epilepsy, CSWS, and ABPE,
which is associated with frontal lobe function,22,23 achieved a
higher beneﬁt from LEV, whereas temporal lobe epilepsy had less
beneﬁt. Several studies found a relatively higher incidence of
frontal foci as the likely principal triggers of bisynchronous
discharges compared with control groups.12,24 These ﬁndings
appeared to contradict the conclusions of Tukel and Jasper that
parasagittal lesions have a propensity to ignite bisynchronous
discharges.6 However, a relatively high incidence of frontal foci
was also found by Niedermeyer in a similar study.25 Another study
reported that the frontal lobe was the most common origin ofTable 3
Epilepsy syndromes and clinical efﬁcacy of LEV. LEV, levetiracetam; SBS, secondary
bilateral synchrony; ABPE, atypical benign partial epilepsy of childhood; FLE, frontal
lobe epilepsy; TLE, temporal lobe epilepsy; CSWS, epilepsy with continuous spike
and wave during slow sleep.
Epilepsy
syndrome
Total
(n)
Responder
(50% reduction
in SBS
frequency)
Seizure free
n % n %
ABPE 2 2 100 2 100
FLE 5 4 80 2 40
TLE 1 0 0 0 0
CSWS 3 2 66.7 2 66.7grand mal attacks.26 Moreover, bisynchronous epileptiform dis-
charges most commonly appear over the frontal lobes.6,24,27 The
reason why the frontal lobes serve as the most common triggers
and principal sites of expression of SBS might be a signiﬁcant
regional variation in the capacity of the cortex to produce
bilaterally synchronous discharges following establishment of
bilaterally symmetrical epileptogenic foci.28 Frontal foci easily
elicited sustained bisynchronous discharges that often spread
diffusely; temporal foci failed to produce bisynchronous dis-
charges. The present results are in agreement with these ﬁndings.
Thus, frontal epileptic origin seizures may obtain the greatest
beneﬁt from LEV. On the other hand, in previous studies, the
thalamus appeared to play a crucial role as a pacemaker of
rhythmic EEG activities such as SBS. In our previous report,
interictal single photon emission computed tomography (SPECT)
revealed thalamic hypoperfusion and ipsilateral cortical region
involvement in children with epilepsy with SBS on EEG.29 In
another report, ictal SPECT showed positive ﬁndings of focal
hyperperfusion in the frontal region and ipsilateral thalamus in
frontal absence.30 It was suspected that early thalamic injury was
associated with CSWS.31 These ﬁndings suggest that the thalamus
may play a role in SBS on EEG. Therefore, epilepsies associated with
the thalamo-cortical network may obtain greater beneﬁt from LEV.
However, the present sample was too small to draw this
conclusion. In addition, although LEV demonstrated good efﬁcacy
in some children with CSWS, some ﬁndings suggested a high
relapse rate in children.4,20 Moreover, the 1 patient with temporal
foci in the present study did not respond, but this number was too
small to ascertain if this was similar to the effect seen in other
studies. Further investigations are needed to clarify these points.
In contrast, it seems interesting that the frontal lobe epilepsies
had a strong reduction in their SBS, but this did not correspond to
seizure freedom, unlike the other epilepsy syndromes. In FLE, it is
not uncommon that the inter-ictal EEG is normal despite frequent
daily seizures. EEG ﬁndings may only correspond to clinical
seizures in FLE, which may affect these ﬁndings. Further
investigations are needed to clarify this point.
The ﬁnal LEV doses that subjects received varied signiﬁcantly.
In our preliminary study, some patients showed improvements of
EEG abnormalities without dose increase after seizure response.
Accordingly, we gave the goal dose to each patient who obtained
seizure response (50% seizure reduction) without adverse effects.
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(drowsiness). One patient (case 11) who showed no seizure
response did not receive the maximal dose of LEV. However, in our
preliminary study, all patients with seizure response showed a
minimal response within the dose of 45 mg/kg/day of LEV.
Accordingly, the variation in dose may potentially have a non-
negligible effect on the results.
No correlation was found between the efﬁcacy for SBS on EEG
and LEV dosage. This ﬁnding contradicted the results by Boon
et al.32 However, LEV does not always decrease seizure frequency
in a dose-dependent manner.33 Further investigations will be
needed to clarify these points.
In the present study, only one patient (9.1%) experienced
adverse events without requiring LEV discontinuation. A relatively
slow titration may result in this low incidence of adverse effects.
LEV can be introduced rapidly, but a relatively slow titration of LEV
may result in it being well-tolerated.
5. Conclusions
This add-on study shows that LEV is an alternative therapy in
refractory childhood epilepsy syndromes. The present data clearly
indicate the usefulness of LEV in reducing both SBS on EEG and
seizure frequency. Frontal epileptic origin seizures may obtain the
greatest beneﬁt from LEV. Since treatment options for refractory
epilepsies are limited, LEV represents an important addition to the
treatments available for refractory childhood epilepsies with SBS
on EEG.
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